#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	15530	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2082	738.4	0	.	n	.	0	C451T	SNP	451	451	C	705	705	T	894	T,C,A	607,220,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	15530	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2082	738.4	1	SNP	n	C1184T	0	.	.	1184	1184	C	1438	1438	C	840	C	783	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	27934	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3646	762.5	0	.	n	.	0	T695C	SNP	695	695	T	1089	1089	C	870	C	798	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	27934	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3646	762.5	0	.	n	.	0	T1971C	SNP	1971	1971	T	2365	2365	C	929	C,T	860,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	27934	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3646	762.5	1	SNP	n	A2045G	0	.	.	2045	2045	A	2439	2439	A	863	A	797	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	27934	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3646	762.5	1	SNP	n	C2597T	0	.	.	2597	2597	C	2991	2991	C	824	C	760	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	27934	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3646	762.5	0	HET	.	.	.	A1638G	.	1638	1638	A	2032	2032	A	876	A,G	441,373	.	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	27	2094	folP	855	855	100.0	folP.l6.c4.ctg.1	1542	135.0	1	SNP	p	R229S	1	.	.	685	687	AGC	997	999	AGC	210;211;209	A;G;C	198;196;194	folP.WHO_Y_01480c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5594	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3463	160.6	1	SNP	p	S91F	1	.	.	271	273	TTC	581	583	TTC	199;200;205	T;T;C	188;188;191	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5594	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3463	160.6	1	SNP	p	D95G	1	.	.	283	285	GGC	593	595	GGC	201;200;199	G;G;C	186;185;185	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5594	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3463	160.6	1	SNP	p	G95N	0	.	.	283	285	GGC	593	595	GGC	201;200;199	G;G;C	186;185;185	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	27	1618	mtrR	633	633	100.0	mtrR.l15.c17.ctg.1	1278	125.7	1	SNP	p	G45D	0	.	.	133	135	GGC	487	489	GGC	237;238;235	G;G;C	217;216;216	mtrR.WHO_X_01389:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	846	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1129	74.4	0	.	n	.	0	A197.	DEL	197	197	A	657	657	A	207	A	191	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	6292	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3090	202.6	1	SNP	p	D86N	0	.	.	256	258	GAC	587	589	GAC	230;232;233	G;A;C	212;209;218	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	6292	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3090	202.6	1	SNP	p	R87W	0	.	.	259	261	CGT	590	592	CGT	236;234;235	C;G;T	222;218;217	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	6292	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3090	202.6	1	SNP	p	R87I	0	.	.	259	261	CGT	590	592	CGT	236;234;235	C;G;T	222;218;217	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	6292	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3090	202.6	1	SNP	p	S87R	1	.	.	259	261	CGT	590	592	CGT	236;234;235	C;G;T	222;218;217	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	6292	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3090	202.6	1	SNP	p	S88P	0	.	.	262	264	TCC	593	595	TCC	236;234;237	T;C;C	219;220;223	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4328	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2504	170.9	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1431	1433	GGC	203;200;201	G,T;G;C	190,1;187;185	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.35.001	penA.35.001	1	1	27	3932	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2544	153.5	1	SNP	p	A311V	0	.	.	931	933	GCC	1299	1301	GCC	206;204;205	G;C;C	183;181;184	penA.35.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.35.001	penA.35.001	1	1	27	3932	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2544	153.5	1	SNP	p	I312M	1	.	.	934	936	ATG	1302	1304	ATG	206;206;204	A;T,C;G	183;185,1;184	penA.35.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.35.001	penA.35.001	1	1	27	3932	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2544	153.5	1	SNP	p	T316P	0	.	.	946	948	ACC	1314	1316	ACC	199;197;198	A;C;C	179;176;177	penA.35.001:1:1:T316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.35.001	penA.35.001	1	1	27	3932	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2544	153.5	1	SNP	p	V316T	1	.	.	946	948	ACC	1314	1316	ACC	199;197;198	A;C;C	179;176;177	penA.35.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.35.001	penA.35.001	1	1	27	3932	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2544	153.5	1	SNP	p	T483S	0	.	.	1447	1449	ACC	1815	1817	ACC	198;197;200	A,C;C;C	179,1;183;187	penA.35.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.35.001	penA.35.001	1	1	27	3932	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2544	153.5	1	SNP	p	A501V	0	.	.	1501	1503	GCG	1869	1871	GCG	218;216;216	G;C;G	174;168;162	penA.35.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.35.001	penA.35.001	1	1	27	3932	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2544	153.5	1	SNP	p	A501P	0	.	.	1501	1503	GCG	1869	1871	GCG	218;216;216	G;C;G	174;168;162	penA.35.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.35.001	penA.35.001	1	1	27	3932	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2544	153.5	1	SNP	p	G542S	0	.	.	1624	1626	GGT	1992	1994	GGT	183;181;179	G;G;T	169;168;162	penA.35.001:1:1:G542S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.35.001	penA.35.001	1	1	27	3932	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2544	153.5	1	SNP	p	G545S	0	.	.	1633	1635	GGC	2001	2003	GGC	170;168;164	G;G;C,T	155;151;147,1	penA.35.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.35.001	penA.35.001	1	1	27	3932	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2544	153.5	1	SNP	p	P551S	0	.	.	1651	1653	CCG	2019	2021	CCG	142;147;147	C,G;C;GCCC,GGCCCCC	105,1;106;99,1	penA.35.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6060	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3084	195.1	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1643	1645	CCG	220;221;219	C;C;G	201;208;202	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2508	porA	1146	1146	99.91	porA.l6.c17.ctg.1	1902	130.8	0	.	p	.	0	M83fs	FSHIFT	247	247	A	588	588	C	204	C	188	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	360	porB1a	984	305	90.61	porB1a.l15.c17.ctg.2	475	27.2	0	.	p	.	0	H217N	NONSYN	649	651	CAT	195	197	AAT	19;19;19	A;A;T	19;19;19	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	360	porB1a	984	305	90.61	porB1a.l15.c17.ctg.2	475	27.2	0	.	p	.	0	D218N	NONSYN	652	654	GAT	198	200	AAT	19;19;19	A;A;T	19;19;19	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	360	porB1a	984	305	90.61	porB1a.l15.c17.ctg.2	475	27.2	0	.	p	.	0	V226A	NONSYN	676	678	GTA	222	224	GCA	17;17;17	G;C;A	17;17;17	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	360	porB1a	984	305	90.61	porB1a.l15.c17.ctg.2	475	27.2	0	.	p	.	0	.	MULTIPLE	700	702	ACT	245	247	GTA	18;18;18	G;T;A	18;18;18	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	360	porB1a	984	305	90.61	porB1a.l15.c17.ctg.2	475	27.2	0	.	p	.	0	N237fs	FSHIFT	709	709	A	254	254	A	18	A	18	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2986	porB1b	1038	1038	99.81	porB1b.l6.c4.ctg.1	1583	186.5	0	.	p	.	0	I45V	NONSYN	133	135	ATT	449	451	GTT	252;249;248	G,T;T,A;T	227,1;222,1;224	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2986	porB1b	1038	1038	99.81	porB1b.l6.c4.ctg.1	1583	186.5	0	.	p	.	0	G48A	NONSYN	142	144	GGA	458	460	GCA	243;245;247	G;C;A	221;222;224	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2986	porB1b	1038	1038	99.81	porB1b.l6.c4.ctg.1	1583	186.5	1	SNP	p	G120K	1	.	.	358	360	AAG	674	676	AAG	221;220;219	A;A;G,A	206;205;200,1	porB1b.WHO_Y_02277c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2986	porB1b	1038	1038	99.81	porB1b.l6.c4.ctg.1	1583	186.5	1	SNP	p	N121D	0	.	.	361	363	AAC	677	679	AAC	222;222;224	A;A;C	206;206;206	porB1b.WHO_Y_02277c:1:1:N121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2986	porB1b	1038	1038	99.81	porB1b.l6.c4.ctg.1	1583	186.5	1	SNP	p	A121N	1	.	.	361	363	AAC	677	679	AAC	222;222;224	A;A;C	206;206;206	porB1b.WHO_Y_02277c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	11270	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	4871	230.4	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1180	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1060	110.6	1	SNP	p	V57M	1	.	.	169	171	ATG	609	611	ATG	239;239;241	A;T;G	222;225;224	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
